Direct Acting Anti-Viral's In Chronic HCV Patients
Direct Acting Anti-Viral's In Chronic HCV Patients
The objective of the study is to determine the safety of DAA's among chronic HCV patients.
 The outcomes of the study are; To determine the frequency of adverse events while receiving
 DAAs with or without RBV and/or Pegylated Interferon To calculate the percentage of patients
 with severity of medical event as per Karch and Lasagna classification To determine the
 percentage of patient having serious adverse event as per ICH Classification
The cross sectional survey data will be collected on a pre-defined questionnaire from
 Gastroenterologist and Hepatologist. The questionnaire will provide us information on
 demographics, relevant patient history, concomitant medication, ongoing treatment plan
 recommended for chronic HCV and adverse event details.

 The questions related to Pharmacovigilance and safety assessment includes the International
 Nonproprietary Names (INN) unless it is prescribed brand of Getz Pharma. All adverse events
 associated with the prescribed treatment will be recorded. Data on outcome assessment will be
 based on action taken due to AE and other reported details. Seriousness of adverse event will
 also be recorded as per the ICH classification and severity of medical event will be assessed
 as per Karch and Lasagna classification.

 All the information will be recorded by the healthcare professionals on the questionnaire
 during direct interaction with the patients.

 Patients' written authorization to use and/or disclose the patient's personal and/or health
 data will be obtained. However, patient data secrecy will follow ICH GCP requirements.
Inclusion Criteria:

 1. Written informed consent

 2. Male or Female patient

 3. Age of patient ≥18 years

 4. Patients already diagnosed with HCV and on DAAs therapy.

 Exclusion Criteria:

 1. Written informed consent

 2. Male or Female patient

 3. Age of patient ≥18 years

 4. Patients already diagnosed with HCV and on DAAs therapy.